Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 13Gliosarcoma 11Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Lung Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Glioma 4Adenocarcinoma, Bronchiolo-Alveolar 4Vaginal Neoplasms 3Oropharyngeal Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sinonasal Squamous Cell Carcinoma × Radiation × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡